What is the optimal treatment approach for iliac bone metastases?

Treatment of Iliac Bone Metastases

For uncomplicated painful iliac bone metastases, single-fraction radiotherapy (8 Gy) is the first-line treatment, combined with bone-targeted agents (denosumab or zoledronate) initiated at diagnosis and continued throughout the disease course 1.

Treatment Algorithm Based on Clinical Presentation

For Uncomplicated Painful Lesions (No Fracture, No Instability)

• Radiotherapy: Single 8-Gy fraction is the standard approach 1

  • Prophylactic dexamethasone should be given alongside analgesics to reduce pain flare 1
  • Antiemetic prophylaxis is recommended for pelvic radiation 1
  • Re-irradiation with single fraction is effective if needed and less toxic than prolonged regimens 1

• Bone-Targeted Agents: Start immediately at diagnosis 1

  • Breast cancer: Zoledronate or denosumab (mandatory, whether symptomatic or not) 1
  • Prostate cancer (castration-resistant): Zoledronate or denosumab (mandatory) 1
  • Lung, renal, other solid tumors: Zoledronate or denosumab if life expectancy >3 months 1

For Structurally Significant or Impending Pathological Fractures

Orthopedic surgery is preferentially indicated over radiotherapy alone 1. The iliac bone, particularly when involving the arcuate line or supra-acetabular region, requires mechanical stabilization to restore weight-bearing capacity.

• Surgical options:

  • Percutaneous fixation with internal cemented screws (FICS) provides rapid pain relief (mean pain score drops from 8.4 to 2.2 at 1 month) and sustained quality of life improvement 2
  • Percutaneous nailing combined with cementoplasty for extensive iliac wing destruction involving the arcuate line 3
  • These minimally invasive techniques show no late adverse events and allow resumed ambulation 2, 3

• Post-operative management: Fractionated radiotherapy is usually recommended after orthopedic fixation to prevent prosthesis failure and reduce need for subsequent surgery 1

For Large Osteolytic Lesions (Mean diameter >9 cm)

Higher-dose fractionated radiotherapy (≥30 Gy in 10-15 fractions) shows better outcomes than single-fraction for extensive iliac lesions 4:

• Pain response: Good in 44%, fair in 25%
• Ambulation restored in 69% of patients
• Bone re-calcification achieved in 36% of cases 4

For Radium-223 Eligible Patients (Prostate Cancer Only)

Radium-223 is indicated for bone-predominant metastatic castration-resistant prostate cancer with symptomatic multiple skeletal metastases 1:

• Improved overall survival by 3.6 months and delayed skeletal events by 5.8 months 1
• Critical caveat: Must be given with concurrent bone-targeted agent (bisphosphonate or denosumab) to prevent osteoporotic fractures 1
• Do NOT combine with abiraterone—this combination increases fracture risk and is contraindicated 1

Primary Tumor-Specific Considerations

• Thyroid follicular carcinoma: Iodine-131 is well-established for bone metastases 1
• Prostate/breast with osteoblastic metastases: Consider bone-seeking beta emitters (strontium-89, samarium-153) for palliation, though bone marrow toxicity limits repeated use 1

Critical Pitfalls to Avoid

1. Never stop denosumab abruptly: Causes rebound osteolysis and multiple vertebral fractures. Transition to bisphosphonate (single 4-5 mg zoledronate dose) after discontinuation 1

2. Do not delay bone-targeted agents: They should be initiated at diagnosis of bone metastasis, not after skeletal events occur 1

3. Do not use radiotherapy alone for impending fractures: It provides pain relief but does not restore bone stability—surgery is required 1

4. Prophylactic surgery is preferred over post-fracture fixation for structurally significant lesions 1

5. For extensive iliac destruction involving weight-bearing areas (arcuate line, supra-acetabular region), radiotherapy alone is insufficient—mechanical stabilization is mandatory for functional restoration 2, 3

Prognosis Context

Iliac bone metastases carry poor prognosis (median survival 2 months in one series), but aggressive local treatment significantly improves quality of life and mobility during remaining survival time 4. Treatment decisions should prioritize rapid pain control and functional restoration over prolonged survival expectations.